Literature DB >> 11321510

Vascular changes in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet.

M Lassila1, J Santisteban, P Finckenberg, P Salmenperä, A Riutta, E Moilanen, I Virtanen, H Vapaatalo, M L Nurminen.   

Abstract

Functional and morphological changes of blood vessels in cyclosporine A (CsA)-induced hypertension and nephrotoxicity were studied in spontaneously hypertensive rats (SHR). The role of the L-arginine-nitric oxide (NO) pathway and the importance of oxidative stress in CsA toxicity were also assessed. SHR (7-8 week old) on a high-sodium diet were treated with CsA (5 mg kg(-1) d(-1) s.c.) for 6 weeks. A proportion of the rats were treated concomitantly with the NO precursor L-arginine (1.7 g kg(-1)d(-1) p.o.). CsA elevated blood pressure and caused renal dysfunction and morphological nephrotoxicity. CsA also impaired mesenteric and renal arterial function and caused structural damage to intrarenal and extrarenal small arteries and arterioles. Medial atrophy of the mesenteric resistance vessels and decreased viability of smooth muscle cells of the thoracic aorta were observed. Renal and arterial damage was associated with the presence of inflammatory cells. CsA did not affect markers of the L-arginine-NO pathway (urinary cyclic GMP excretion or endothelial or inducible NO synthase expression in kidney, aorta or heart) or oxidative stress (urinary excretion of 8-isoprostaglandin F2alpha, plasma urate concentration or total radical trapping capacity). Concomitant L-arginine treatment did not affect CsA-induced changes in blood pressure or histological findings but tended to alleviate the arterial dysfunction. The renal and cardiovascular toxicity of CsA was associated with arterial dysfunction and morphological changes in small arteries and arterioles in SHR on a high-sodium diet. The findings did not support the role of oxidative stress or a defect in the L-arginine-NO pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11321510

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  5 in total

1.  Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.

Authors:  Abraham J Wilhelm; Peer de Graaf; Agnes I Veldkamp; Jeroen J W M Janssen; Peter C Huijgens; Eleonora L Swart
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

2.  Endothelial nitric oxide synthase gene variation associated with chronic kidney disease after liver transplant.

Authors:  Kiran Bambha; W Ray Kim; Charles B Rosen; Rachel A Pedersen; Cynthia Rys; Christopher P Kolbert; Julie M Cunningham; Terry M Therneau
Journal:  Mayo Clin Proc       Date:  2010-09       Impact factor: 7.616

3.  Cyclosporine stimulates the renal epithelial sodium channel by elevating cholesterol.

Authors:  Jing Wang; Zhi-Ren Zhang; Chu-Fang Chou; You-You Liang; Yuchun Gu; He-Ping Ma
Journal:  Am J Physiol Renal Physiol       Date:  2008-12-17

4.  Clinical and radiological spectrum of posterior reversible encephalopathy syndrome.

Authors:  Sang-Duk Yoon; Byung-Moon Cho; Sae-Moon Oh; Se-Hyuck Park; In-Bock Jang; Jong-Young Lee
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2013-09-30

5.  Endothelin-1 receptor antagonists protect the kidney against the nephrotoxicity induced by cyclosporine-A in normotensive and hypertensive rats.

Authors:  A Caires; G S Fernandes; A M Leme; B Castino; E A Pessoa; S M Fernandes; C D Fonseca; M F Vattimo; N Schor; F T Borges
Journal:  Braz J Med Biol Res       Date:  2017-12-11       Impact factor: 2.590

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.